Want to see VTGN full AI Analyst Report?
VTGN Stock Chart & Stats
$0.63
-$0.08(-2.56%)
At close: 4:00 PM EST
$0.63
-$0.08(-2.56%)
Day’s Range― - ―
52-Week Range$0.20 - $5.14
Previous CloseN/A
Volume188.19K
Average Volume (3M)1.23M
Market Cap
$9.40M
Enterprise Value-$21.72
Total Cash (Recent Filing)$45.40M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding41,032,450
10 Day Avg. Volume1,055,596
30 Day Avg. Volume1,225,812
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.61
Price to Sales (P/S)17.15
P/FCF Ratio-0.33
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside58.73% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$500.00K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVistaGen's very low reported debt and ~0.03 debt-to-equity materially reduce near-term leverage risk. Lower fixed financing obligations preserve flexibility to pursue additional trials or partnerships without large interest burdens, supporting operational optionality while clinical programs advance.
Robust Long-Term Safety ExposureMeeting ICH E1 exposure thresholds with substantial multi-month subject exposure builds a durable safety database for long-term treatment labeling. This strengthens the regulatory case for repeat-dose registrational trials and reduces structural regulatory risk versus programs lacking such exposure.
Differentiated Platform And Pipeline BreadthThe non-systemic pherine nose-to-brain delivery offers a potential competitive advantage versus systemic anxiolytics by lowering abuse and systemic side-effect risk. Combined with multiple programs (fasedienol, itruvone, refisolone), the platform gives structural product diversification if efficacy is confirmed, reducing single-asset dependency.
Bears Say
Phase 3 Efficacy FailureThe PALISADE-4 efficacy miss is a durable negative: it forces a strategic pivot to longer-term registrational designs, increases the likelihood of additional costly trials, delays potential approval timelines and reduces the near-term probability of commercial success for the lead asset.
High And Worsening Cash BurnConsistent, deepening operating cash outflows indicate heavy funding dependence. Real cash burn necessitates recurring financings or partnerships, raising dilution risk and constraining the firm's ability to advance multiple late-stage programs simultaneously without materially altering capital structure or strategic scope.
Volatile, Minimal Revenue And Deepening LossesAs a pre-commercial developer, VistaGen lacks recurring product revenue and shows widening net losses and negative margins. Persistent unprofitability erodes equity and increases refinancing pressure, making long-term sustainability contingent on successful clinical outcomes or sizable external financing/partnerships.
VistaGen Therapeutics News
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.20 and its highest was $5.14 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $9.40M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Jun 15, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.337 by -$0.033.
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -0.37.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 41,032,450 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.337. Following the earnings report the stock price went up 20.419%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
VTGN Stock 12 Month Forecast
Average Price Target
$1.00
▲(58.73% Upside)
Technical Analysis
MacroGenics
―
Ovid Therapeutics
―
Spero Therapeutics
―
Inhibikase Therapeutics
―
Surrozen
―
Ownership Overview
0.42% Insiders
4.68% Mutual Funds
21.48% Other Institutional Investors
68.49% Public Companies and
Individual Investors